Antithyroid drug therapy in pregnancy and risk of congenital anomalies: Systematic review and meta-analysis.
carbimazole
hyperthyroidism congenital anomalies
methimazole
pregnancy antithyroid drugs
propylthiouracil
Journal
Clinical endocrinology
ISSN: 1365-2265
Titre abrégé: Clin Endocrinol (Oxf)
Pays: England
ID NLM: 0346653
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
12
10
2021
received:
15
09
2021
accepted:
21
10
2021
pubmed:
1
12
2021
medline:
6
5
2022
entrez:
30
11
2021
Statut:
ppublish
Résumé
The risk of congenital anomalies following in utero exposure to thionamide antithyroid drugs (ATDs) is unresolved. Observational studies are contradictory and existing meta-analyses predate and preclude more recent studies. We undertook an updated meta-analysis of congenital anomaly risk in women exposed to carbimazole or methimazole (CMZ/MMI), propylthiouracil (PTU), or untreated hyperthyroidism in pregnancy. We searched Medline, Embase, and the Cochrane database for articles published up till August 2021. We pooled separate crude and adjusted risk estimates using random effects models and subgroup analyses to address heterogeneity. We identified 16 cohort studies comprising 5957, 15,785, and 15,666 exposures to CMZ/MMI, PTU, and untreated hyperthyroidism, respectively. Compared to nondisease controls, adjusted risk ratio (RR) and 95% confidence intervals (95% CIs) for congenital anomalies was increased for CMZ/MMI (RR, 1.28; 95% CI, 1.06-1.54) and PTU (RR, 1.16; 95% CI, 1.08-1.25). Crude risk for CMZ/MMI was increased relative to PTU (RR, 1.20; 95% CI, 1.01-1.43). Increased risk was also seen with exposure to both CMZ/MMI and PTU, that is, women who switched ATDs in pregnancy (RR, 1.51; 95% CI, 1.14-1.99). However, the timing of ATD switch was highly variable and included prepregnancy switches in some studies. The excess number of anomalies per 1000 live births was 17.2 for patients exposed to CMZ/MMI, 9.8, for PTU exposure, and 31.4 for exposure to both CMZ/MMI and PTU. Risk in the untreated group did not differ from control or ATD groups. The untreated group was however highly heterogeneous in terms of thyroid status. Subgroup analysis showed more positive associations in studies with >500 exposures and up to 1-year follow-up. ATD therapy carries a small risk of congenital anomalies which is higher for CMZ/MMI than for PTU and does not appear to be reduced by switching ATDs in pregnancy. Due to key limitations in the available data, further studies will be required to clarify the risks associated with untreated hyperthyroidism and with switching ATDs in pregnancy.
Substances chimiques
Antithyroid Agents
0
Methimazole
554Z48XN5E
Propylthiouracil
721M9407IY
Carbimazole
8KQ660G60G
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
857-868Informations de copyright
© 2021 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.
Références
Andersen SL, Olsen J, Carlé A, Laurberg P. Hyperthyroidism incidence fluctuates widely in and around pregnancy and is at variance with some other autoimmune diseases: a Danish population-based study. J Clin Endocrinol Metab. 2015;100(3):1164-1171.
Andersen SL, Olsen J, Wu CS, Laurberg P. Spontaneous abortion, stillbirth and hyperthyroidism: a danish population-based study. Eur Thyroid J. 2014;3(3):164-172.
Okosieme OE, Lazarus JH. Important considerations in the management of Graves' disease in pregnant women. Expert Rev Clin Immunol. 2015;11(8):947-957.
Millar LK, Wing DA, Leung AS, Koonings PP, Montoro MN, Mestman JH. Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism. Obstet Gynecol. 1994;84(6):946-949.
Burch HB, Cooper DS. Anniversary review: antithyroid drug therapy: 70 years later. Eur J Endocrinol. 2018;179(5):R261-R274.
Francis T, Francis N, Lazarus JH, Okosieme OE. Safety of antithyroid drugs in pregnancy: update and therapy implications. Expert Opin Drug Saf. 2020;19(5):565-576.
Taylor PN, Vaidya B. Side effects of anti-thyroid drugs and their impact on the choice of treatment for thyrotoxicosis in pregnancy. Eur Thyroid J. 2012;1(3):176-185.
Clementi M, Di Gianantonio E, Pelo E, Mammi I, Basile RT, Tenconi R. Methimazole embryopathy: delineation of the phenotype. Am J Med Genet. 1999;83(1):43-46.
Khan I, Okosieme O, Lazarus J. Antithyroid drug therapy in pregnancy: a review of guideline recommendations. Expert Rev Endocrinol Metab. 2017;12(4):269-278.
Alexander EK, Pearce EN, Brent GA, et al. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid 2017. 2017;27(3):315-389.
Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. European Thyroid Association guideline for the management of Graves' hyperthyroidism. Eur Thyroid J. 2018;7(4):167-186.
Andersen SL, Knøsgaard L, Olsen J, Vestergaard P, Andersen S. Maternal thyroid function, use of antithyroid drugs in early pregnancy, and birth defects. J Clin Endocrinol Metab. 2019;104(12):6040-6048.
Seo GH, Kim TH, Chung JH. Antithyroid drugs and congenital malformations: a nationwide Korean cohort study. Ann Intern Med. 2018;168(6):405-413.
Momotani N, Ito K, Hamada N, Ban Y, Nishikawa Y, Mimura T. Maternal hyperthyroidism and congenital malformation in the offspring. Clin Endocrinol. 1984;20(6):695-700.
Andersen SL, Andersen S. Antithyroid drugs and birth defects. Thyroid Res. 2020;13:11.
Li H, Zheng J, Luo J, et al. Congenital anomalies in children exposed to antithyroid drugs in-utero: a meta-analysis of cohort studies. PLOS One. 2015;10(5):e0126610.
Li X, Liu GY, Ma JL, Zhou L. Risk of congenital anomalies associated with antithyroid treatment during pregnancy: a meta-analysis. Clinics. 2015;70(6):453-459.
Song R, Lin H, Chen Y, Zhang X, Feng W. Effects of methimazole and propylthiouracil exposure during pregnancy on the risk of neonatal congenital malformations: a meta-analysis. PLOS One. 2017;12(7):e0180108.
Turunen S, Vääräsmäki M, Lahesmaa-Korpinen AM, et al. Maternal hyperthyroidism and pregnancy outcomes: a population-based cohort study. Clin Endocrinol. 2020;93(6):721-728.
Yoshihara A, Noh JY, Watanabe N, et al. Exposure to propylthiouracil in the first trimester of pregnancy and birth defects: a study at a single institution. J Endocr Soc. 2021;5(3):bvaa204.
El Khalil N, Lupattelli A, Nordeng H. Antithyroid drug treatment and pregnancy outcomes among women with hyperthyroidism in pregnancy: a Norwegian population-based registry-linkage study. Norsk Epidemiologi. 2021;29(1-2):71-84.
Morales DR, Fonkwen L, Nordeng HME. Antithyroid drug use during pregnancy and the risk of birth defects in offspring: systematic review and meta-analysis of observational studies with methodological considerations. Br J Clin Pharmacol. 2021;87:3890-3900.
Wells GSB, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25(20):3443-3457.
Schünemann HJ, Vist GE, Higgins JP, et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M., Li T., Page M., Welch V., eds. Cochrane handbook for systematic reviews of interventions version 62 (updated February 2021). Cochrane; 2021.
Andersen SL, Lonn S, Vestergaard P, Torring O. Birth defects after use of antithyroid drugs in early pregnancy: a Swedish nationwide study. Eur J Endocrinol. 2017;177(4):369-378.
Andersen SL, Olsen J, Wu CS, Laurberg P. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab. 2013;98(11):4373-4381.
Chen CH, Xirasagar S, Lin CC, Wang LH, Kou YR, Lin HC. Risk of adverse perinatal outcomes with antithyroid treatment during pregnancy: a nationwide population-based study. BJOG. 2011;118(11):1365-1373.
Di Gianantonio E, Schaefer C, Mastroiacovo PP, et al. Adverse effects of prenatal methimazole exposure. Teratology. 2001;64(5):262-266.
Korelitz JJ, McNally DL, Masters MN, Li SX, Xu Y, Rivkees SA. Prevalence of thyrotoxicosis, antithyroid medication use, and complications among pregnant women in the United States. Thyroid. 2013;23(6):758-765.
Lo JC, Rivkees S, Chandra M, Gonzalez JR, Korelitz JJ, Kuzniewicz MW. Gestational thyrotoxicosis, antithyroid drug use and neonatal outcomes within an integrated healthcare delivery system. Thyroid. 2015;25:698-705.
Wing DA, Millar LK, Koonings PP, Montoro MN, Mestman JH. A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancy. Am J Obstet Gynecol. 1994;170(1 Pt 1):90-95.
Yoshihara A, Noh J, Yamaguchi T, et al. Treatment of graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab. 2012;97:2396-2403.
Rosenfeld H, Ornoy A, Shechtman S, Diav-Citrin O. Pregnancy outcome, thyroid dysfunction and fetal goitre after in utero exposure to propylthiouracil: a controlled cohort study. Br J Clin Pharmacol. 2009;68(4):609-617.
Hawken C, Sarreau M, Bernardin M, et al. Management of Graves' disease during pregnancy in the Poitou-Charentes Region. Ann Endocrinol. 2016;77(5):570-577.
Andersen SL, Andersen S. Timing of shift in antithyroid drug therapy and birth defects. Thyroid. 2019;29(1):155-156.
Okosieme OE, Khan I, Taylor PN. Preconception management of thyroid dysfunction. Clin Endocrinol. 2018;89(3):269-279.
Dolk H, Loane M, Garne E. The prevalence of congenital anomalies in Europe. Adv Exp Med Biol. 2010;686:349-364.
Andersen SL, Olsen J, Wu CS, Laurberg P. Severity of birth defects after propylthiouracil exposure in early pregnancy. Thyroid. 2014;24(10):1533-1540.